Bharat Biotech's Covaxin, which also happens to be India's indigenous vaccine, will be at least 60 per cent effective against COVID-19 and the company is aiming to launch the vaccine in the Q2 of 2021.
Sai D Prasad, President, Quality Operations at Bharat Biotech, in an interview with India Today, said the company is aiming for at least 60 per cent effectiveness and it could be more than that.
Bharat Biotech and ICMR are working on Covaxin, one of the indigenous coronavirus vaccine candidates being developed in India.
The US, UK and Russia have their own candidates competing to be the first and most effective vaccine in the world.?Pfizer and Moderna, two drugmakers in the vaccine race, have claimed that their vaccine is at least 95 per cent effective.
Bharat Biotech commenced Phase 3 trials of the vaccine earlier this month.
The trials are conducted involving 26,000 volunteers across 25 centres in India in partnership with ICMR.
Earlier, a government scientist said that Covaxin could be launched as early as February next year.
Senior ICMR scientist Rajni Kant recently said, "The vaccine has shown good efficacy." Kant is also a member of its COVID-19 task-force.